Annual EBITDA
-$10.95 M
+$2.89 M+20.89%
31 December 2023
Summary:
Qualigen Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$10.95 million, with the most recent change of +$2.89 million (+20.89%) on 31 December 2023. During the last 3 years, it has fallen by -$673.80 thousand (-6.56%). QLGN annual EBITDA is now -6.56% below its all-time high of -$10.28 million, reached on 01 December 2020.QLGN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$1.39 M
-$173.70 K-14.31%
30 September 2024
Summary:
Qualigen Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$1.39 million, with the most recent change of -$173.70 thousand (-14.31%) on 30 September 2024. Over the past year, it has increased by +$1.48 million (+51.60%). QLGN quarterly EBITDA is now -487.10% below its all-time high of -$236.40 thousand, reached on 30 September 2019.QLGN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$6.73 M
+$1.48 M+18.02%
30 September 2024
Summary:
Qualigen Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$6.73 million, with the most recent change of +$1.48 million (+18.02%) on 30 September 2024. Over the past year, it has increased by +$4.51 million (+40.09%). QLGN TTM EBITDA is now -1343.30% below its all-time high of -$466.50 thousand, reached on 30 June 2019.QLGN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
QLGN EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +20.9% | +51.6% | +40.1% |
| 3 y3 years | -6.6% | +70.6% | +62.1% |
| 5 y5 years | - | -487.1% | -857.9% |
QLGN EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -6.6% | +51.0% | -14.3% | +71.8% | at high | +69.8% |
| 5 y | 5 years | -6.6% | +51.0% | -487.1% | +92.5% | -857.9% | +79.1% |
| alltime | all time | -6.6% | +51.0% | -487.1% | +92.5% | -1343.3% | +79.1% |
Qualigen Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.39 M(+14.3%) | -$6.73 M(-18.0%) |
| June 2024 | - | -$1.21 M(-35.9%) | -$8.21 M(-19.1%) |
| Mar 2024 | - | -$1.89 M(-15.3%) | -$10.15 M(-7.3%) |
| Dec 2023 | -$10.95 M(-20.9%) | -$2.24 M(-22.0%) | -$10.95 M(-2.6%) |
| Sept 2023 | - | -$2.87 M(-9.1%) | -$11.24 M(-5.1%) |
| June 2023 | - | -$3.16 M(+17.3%) | -$11.84 M(-7.0%) |
| Mar 2023 | - | -$2.69 M(+6.5%) | -$12.73 M(-14.9%) |
| Dec 2022 | -$13.84 M | -$2.53 M(-27.2%) | -$14.97 M(-12.0%) |
| Sept 2022 | - | -$3.47 M(-14.3%) | -$17.00 M(-6.9%) |
| June 2022 | - | -$4.05 M(-17.8%) | -$18.25 M(-15.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$4.92 M(+8.0%) | -$21.52 M(-3.6%) |
| Dec 2021 | -$22.32 M(+117.2%) | -$4.56 M(-3.5%) | -$22.32 M(+25.7%) |
| Sept 2021 | - | -$4.72 M(-35.4%) | -$17.77 M(-15.7%) |
| June 2021 | - | -$7.31 M(+27.6%) | -$21.08 M(-34.5%) |
| Mar 2021 | - | -$5.73 M(-28.6%) | -$32.20 M(+21.7%) |
| Dec 2020 | -$10.28 M | - | - |
| Sept 2020 | - | -$8.03 M(-56.4%) | -$26.47 M(+41.7%) |
| June 2020 | - | -$18.44 M(+7699.5%) | -$18.67 M(+2556.8%) |
| Sept 2019 | - | -$236.40 K(-49.3%) | -$702.90 K(+50.7%) |
| June 2019 | - | -$466.50 K | -$466.50 K |
FAQ
- What is Qualigen Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Qualigen Therapeutics?
- What is Qualigen Therapeutics annual EBITDA year-on-year change?
- What is Qualigen Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Qualigen Therapeutics?
- What is Qualigen Therapeutics quarterly EBITDA year-on-year change?
- What is Qualigen Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Qualigen Therapeutics?
- What is Qualigen Therapeutics TTM EBITDA year-on-year change?
What is Qualigen Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of QLGN is -$10.95 M
What is the all time high annual EBITDA for Qualigen Therapeutics?
Qualigen Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$10.28 M
What is Qualigen Therapeutics annual EBITDA year-on-year change?
Over the past year, QLGN annual earnings before interest, taxes, depreciation & amortization has changed by +$2.89 M (+20.89%)
What is Qualigen Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of QLGN is -$1.39 M
What is the all time high quarterly EBITDA for Qualigen Therapeutics?
Qualigen Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$236.40 K
What is Qualigen Therapeutics quarterly EBITDA year-on-year change?
Over the past year, QLGN quarterly earnings before interest, taxes, depreciation & amortization has changed by +$1.48 M (+51.60%)
What is Qualigen Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of QLGN is -$6.73 M
What is the all time high TTM EBITDA for Qualigen Therapeutics?
Qualigen Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$466.50 K
What is Qualigen Therapeutics TTM EBITDA year-on-year change?
Over the past year, QLGN TTM earnings before interest, taxes, depreciation & amortization has changed by +$4.51 M (+40.09%)